Cardioprotective Effects of Dapagliflozin and Exenatide
Cardioprotective Effects of Dapagliflozin and Exenatide
批准号:
367395
负责人:
Zarrin Khat Dorrin
金额:
$1.27万
依托单位:
依托单位国家:
加拿大
项目类别:
Studentship Programs
财政年份:
2016
资助国家:
加拿大
项目状态:
已结题
起止时间:
2016-12-01 至 2017-12-01
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Ischemic cardiovascular disease (CVD) affects a high proportion of the world population. Subjects with type-2 diabetes (T2D) are at particularly high risk of major adverse cardiovascular events (MACE), with CVD representing their leading cause of morbidit
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Cardioprotective benefits of combination treatment with a sodium-glucose co-transporter-2 inhibitor and a glucagon-like peptide-1 receptor agonist.
-
批准号:404134
-
项目类别:Studentship Programs
-
资助金额:$7.65万
-
财政年份:2018
-
负责人:Zarrin Khat Dorrin
-
依托单位:
Cardioprotective benefits of combination treatment with a sodium-glucose co-transporter-2 inhibitor and a glucagon-like peptide-1 receptor agonist.
-
批准号:396625
-
项目类别:Studentship Programs
-
资助金额:$10.93万
-
财政年份:2018
-
负责人:Zarrin Khat Dorrin
-
依托单位:
海外基金